A Systematic Literature Review of Real-World Evidence in Post-Transplant Lymphoproliferative Disorder

Conclusions: To the best of our knowledge, this is the first comprehensive SLR to examine the published real-world evidence in patients with PTLD. Our SLR reveals important differences with respect to methodology and reporting of real-world published studies assessing the current landscape in PTLD. Additional large, high-quality studies employing more rigorous study methodology are required to understand the current landscape of PTLD in the real-world setting.DisclosuresXu: Atara Biotherapeutics, Inc: Employment, Equity Ownership. Forsythe: Novartis: Consultancy. Barlev: Atara Biotherapeutics, Inc: Employment, Equity Ownership. Watson: Atara Biotherapeutics, Inc: Employment, Equity Ownership.

Source: Blood - November 21, 2018 Category: Hematology Authors: Xu, H., Forsythe, A., Barlev, A., Rashid, N., Watson, C. Tags: 902. Health Services Research-Malignant Diseases Source Type: research